At yesterday’s Oncology Innovation Day, Pfizer laid out its business strategy which includes building up its biologics business, specifically antibody-drug conjugates and bispecific antibodies.
Tag Archive for: drug pipeline
Despite this setback, AstraZeneca is looking to differentiate in the DKD space with its pipeline drug, zibotentan. If approved, having another treatment option could be of high value to physicians looking to find an optimal treatment of choice for individuals with DKD.
The Swiss pharma’s dealmaking momentum continues in early 2024 with the acquisition of German biotech MorphoSys in an effort to strengthen its oncology portfolio.
Takeda has flagged this year as a rebuilding phase. It is seeking to deepen its bench of drugs in development as it loses sales exclusivity on main sellers, such as blood pressure drug Azilva in Japan and hyperactivity drug Vyvanse in the United States.
The three drug candidates to be developed with Merck belong to the class known as antibody drug conjugates (ADC) and are in various stages of clinical development for the treatment of multiple solid cancer tumors.
The pipeline culling comes as Roche sustains a slight dip in sales. From January to September 2023, the pharma group made over $49 billion, compared with $52.48 billion during the same period in 2022.
The Massachusetts Biotechnology Council, the nation’s oldest biotech trade association, released its 2023 Industry Snapshot on September 6. The report found that biotech and pharmaceutical companies in Massachusetts added more research and development and biomanufacturing jobs than in most other states in 2022.
While the shooting star Lagevrio pushed Merck’s top line to nearly $60 billion in 2022, the rest of the company’s portfolio is catching up.
In 2022, Sanofi’s adherence to its strategy has yielded an expanded pipeline, greater sales and net income, and progress in the use of artificial intelligence.